Introduction
============

As a complex disorder resulting from the combined effects of multiple environmental and genetic factors, prostate cancer (PCa) is the second leading cause of cancer death in men.[@b1-cmar-11-2039] In Europe, it accounts for \>92,300 deaths annually.[@b2-cmar-11-2039] As a routine assay test in clinic, prostate-specific antigen (PSA) in serum is not specific for PCa, some evaluated PSA levels may induce false-positive due to infection or hyperplasia. Therefore, it is necessary to find novel effective biomarkers to diagnose PCa.

MicroRNAs, a family of small noncoding RNAs (19±22 nucleotides), are stable and easy to accurately measure. MicroRNAs are differentially expressed in normal tissues and cancers, contributing to cancer development and progression.[@b3-cmar-11-2039] MicroRNA-21(miR-21), an anti-apoptotic agent functioning via p53 network, can target and inhibit tumor suppressor gene *PTEN* expression to promote PCa cell proliferation and invasion.[@b4-cmar-11-2039],[@b5-cmar-11-2039] MicroRNA-30c (miR-30c) has been acknowledged as a tumor suppressor in various human cancers, such as ovarian cancer, gastric cancer, and PCa.[@b6-cmar-11-2039]

With respect to diagnostic abilities of miR-21 and miR-30c for PCa, several studies have been conducted, but their results are inconclusive.[@b7-cmar-11-2039]--[@b14-cmar-11-2039] For example, Porzycki et al found specificity (SPE) of miR-21 to diagnose PCa was 0.75, while Yang et al found it could reach 0.93.[@b8-cmar-11-2039],[@b9-cmar-11-2039] What's more, Huang found sensitivity (SEN) of miR-30c was 0.82, while Chen et al found it was only 0.6.[@b11-cmar-11-2039],[@b14-cmar-11-2039] In order to precisely assess the diagnostic values of miR-21 and miR-30c for PCa, this meta-analysis is performed.

Methods
=======

This meta-analysis was conducted according to the guidelines of the PRISMA statement ([Table S1](#SD1-cmar-11-2039){ref-type="supplementary-material"}).[@b15-cmar-11-2039]

Eligibility criteria
--------------------

This meta-analysis selected the patients diagnosed as PCa and the control consisted of healthy people or patients with benign prostate disease. The index tests, which included miR-21 and miR-30c from serum, plasma, mononuclear cell, and tissue, were assessed by fluorescence quantitative PCR. Reference standard was histopathological test, PCa was diagnosed based on histopathological confirmation.

Studies were included if they met following inclusion criteria: 1) studies were designed to evaluate the diagnostic performance of miR-21 or miR-30c for PCa; 2) PCa was diagnosed based on histopathological confirmation and the control group consisted of healthy people or patients with benign prostate disease; 3) 2×2 contingency tables could be directly extracted or calculated; and 4) articles were written in English.

Search strategy
---------------

Articles published prior to September 6, 2018, were systematically searched in the databases of PubMed, Embase, and Web of Knowledge. Search terms were as follows: ("microRNA" or "miRNA" or "miR") and ("prostate cancer" or "prostate carcinoma") and ("diagnosis" or "sensitivity" or "specificity"). Search strategy is shown in [Table S2](#SD2-cmar-11-2039){ref-type="supplementary-material"}. In addition, cited references from relevant articles were examined to select other relevant articles. Two reviewers independently searched the articles. Any disagreements between the two reviewers were resolved by discussion.

Study selection
---------------

The titles and abstracts of the identified articles were examined by two reviewers. Those articles falling under the exclusion criteria (reviews, case reports, letters, comments, conference abstracts, or meta-analyses; animal studies; duplicate studies) were not considered. The full texts were then rescreened and evaluated more thoroughly for eligibility using the same exclusion criteria. Disagreement between the two reviewers was discussed until a consensus was reached.

Data extraction
---------------

The following data were extracted or calculated from retrieved articles by the two reviewers: first author, year of publication, country of participants, specimen type, source of control group, sample size, microRNAs as control for normalization, microRNAs as biomarker, relative expressions in case group compared with control group, diagnostic SEN and SPE values, values of true positive (TP), false positive (FP), false negative (FN) and true negative (TN).

Methodological quality assessment
---------------------------------

Two reviewers assessed the methodological quality of included studies according to the quality assessment of diagnostic accuracy studies-2 (QUADAS-2) tool.[@b16-cmar-11-2039] Patient selection, index test, reference standard, flow, and timing were used to evaluate the risk of bias and the first three domains were applied to assess applicability concerns.

Statistical analysis
--------------------

Statistical analyses were undertaken utilizing Stata 12.0 (StataCorp, College Station, TX, USA) and Meta-Disc 1.4 (Cochrane Colloquium, Barcelona, Spain). Diagnostic threshold effects were inspected with the Spearman rank correlation analysis. Heterogeneity was measured using Cochrane-Q test and *I*^2^ index. *P*\<0.05 for Q test or *I*^2^ \>50% designated heterogeneity. The pooled SEN and SPE, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic score (DS), diagnostic odds ratio (DOR), and area under curve (AUC) of the summary receiver operating characteristic (SROC) curve with the corresponding 95% CI were calculated using a bivariate binomial mixed model. Deeks' funnel plot asymmetry analysis was performed to identify publication bias. Sensitivity analysis was conducted to assess the stability.

Results
=======

Literature search and study characteristics
-------------------------------------------

A total of 420 records were identified through database searching. After removing duplicates, the titles and abstracts for 280 records were screened for eligibility. Of these, 46 records were identified and full-text articles were retrieved. Thirty-eight manuscripts were excluded through assessment of the full-text articles and eight remaining articles encompassing ten studies were included in the meta-analysis ([Figure 1](#f1-cmar-11-2039){ref-type="fig"}).

The ten included studies owned 1,371 participants (737 PCa patients and 634 controls). Their characteristics and the numbers of TP, FP. FN, and TN with the corresponding SEN, SPE are listed in [Table 1](#t1-cmar-11-2039){ref-type="table"}. The number of included studies for miR-21 and miR-30c were, respectively, six and four. Countries of participants for miR-21 involved Poland, China, and Egypt, while miR-30c only involved China. Relative expressions of miR-21 in case group were higher than that in control group. On the contrary, relative expressions of miR-30c were lower in case group. Two studies assessed miR-30c from PCa cancer tissue and PCa adjacent normal tissue,[@b7-cmar-11-2039], [@b11-cmar-11-2039] and other two studies assessed miR-30c from plasma of PCa patients and control group.[@b14-cmar-11-2039] Studies assessed miR-21 from serum, plasma, mononuclear cell of PCa patients, and control group.

Methodological quality assessment
---------------------------------

Quality assessment of included studies was conducted using the QUADAS-2 tool ([Figures 2](#f2-cmar-11-2039){ref-type="fig"} and [3](#f3-cmar-11-2039){ref-type="fig"}). The majority of included studies satisfied most domains of QUADAS-2. The unclear situation existed in the domains of patient selection and index test because there were variations in control group, specimen, and microRNAs as control for normalization.

Diagnostic values
-----------------

For miR-21, the Spearman rank correlation coefficient was --0.841 (*P*=0.036), suggesting that there were no diagnostic threshold effects. The pooled SEN and SPE were, respectively, 0.91 (95% CI: 0.87--0.94) and 0.88 (95% CI: 0.82--0.93) ([Figure 4](#f4-cmar-11-2039){ref-type="fig"}). *I*^2^ for SEN and SPE were, respectively, 0% (*P*=0.58) and 48.9% (*P*=0.08), showing no significant heterogeneity among studies. The pooled PLR and NLR were, respectively, 7.74 (95% CI: 4.81--12.47) and 0.1 (95% CI: 0.06--0.15) ([Figure 5](#f5-cmar-11-2039){ref-type="fig"}). The pooled DS and DOR were, respectively, 4.35 (95% CI: 3.54--5.16) and 77.64 (95% CI: 34.64--174.02) ([Figure 6](#f6-cmar-11-2039){ref-type="fig"}). AUC of SROC curve was 0.95 (95% CI: 0.93--0.97) ([Figure 7](#f7-cmar-11-2039){ref-type="fig"}).

For miR-30c, the Spearman rank correlation coefficient was 0.80 (*P*=0.2), suggesting no existence of diagnostic threshold effects. The pooled SEN and SPE were, respectively, 0.74 (95% CI: 0.65--0.81) and 0.78 (95% CI: 0.72--0.83) ([Figure 8](#f8-cmar-11-2039){ref-type="fig"}). *I*^2^ for SEN and SPE were, respectively, 67.69% (*P*=0.03) and 21.41% (*P*=0.28), revealing that significant heterogeneities existed among studies. The pooled PLR and NLR were, respectively, 3.39 (95% CI: 2.69--4.26) and 0.34 (95% CI: 0.26--0.44) ([Figure 9](#f9-cmar-11-2039){ref-type="fig"}). The pooled DS and DOR were, respectively, 2.31 (95% CI: 1.94--2.68) and 10.06 (95% CI: 6.96--14.55) ([Figure 10](#f10-cmar-11-2039){ref-type="fig"}). AUC of SROC curve was 0.83 (95% CI: 0.79--0.86) ([Figure 7](#f7-cmar-11-2039){ref-type="fig"}).

Publication bias
----------------

As shown in Deeks' funnel plots ([Figure 11](#f11-cmar-11-2039){ref-type="fig"}), publication biases were likely absent with symmetrical funnel shapes. The *P*-values for the funnel plot asymmetry tests (*P*=0.43 for miR-21 and *P*=0.95 for miR-30c) confirmed lack of publication biases.

Sensitivity analysis
--------------------

Sensitivity analysis was performed by eliminating studies one by one. As shown in [Table S3](#SD3-cmar-11-2039){ref-type="supplementary-material"}, the pooled SEN and corresponding heterogeneities of miR-21 and miR-30c were not dominantly influenced by removing any study.

Discussion
==========

The pooled SEN and SPE of miR-21 were, respectively, 0.91 and 0.88, and the AUC of SROC was 0.95, presenting a good diagnostic ability of miR-21. The pooled PLR of 7.74 indicated that PCa probability increased by 7.74-fold with positive miR-21 result. Conversely, the pooled NLR of 0.1 showed the probability could only be 10% when miR-21 result was negative. As a combination of PLR and NLR, DOR is a meaningful diagnostic index. With a DOR value of 77.64, it was confirmed that miR-21 could be a good diagnostic biomarker for PCa. Sensitivity analysis showed that the conclusion of this meta-analysis was robust. There is a research which suggests that miR-21 and androgen receptor axis can exert oncogenic effects in prostate tumors by downregulating transforming growth factor beta receptor II.[@b17-cmar-11-2039]

For miR-30c, this meta-analysis showed that pooled SEN and SPE were, respectively, 0.74 and 0.78; furthermore AUC of SROC was 0.83, presenting a moderate diagnostic ability of miR-30c. Significant heterogeneities were found among included studies. Although sensitivity analysis was carried out, it was still hard to identify which study was the source of heterogeneities.

Three previous meta-analyses (by Yin et al, Ouyang et al, and Yang et al) also reported the diagnostic value of microRNAs for PCa,[@b18-cmar-11-2039]--[@b20-cmar-11-2039] we read them carefully with great interest. The number for miR-21 of enrolled studies by a previous meta-analysis (by Yin)[@b18-cmar-11-2039] was less than our meta-analysis. Other two meta-analyses (by Ouyang et al and Yang et al)[@b19-cmar-11-2039],[@b20-cmar-11-2039] only focused on overall microRNAs but not each single microRNA, inevitably brought about significant heterogeneities, lower quality assessments, and meaninglessness in application. Another previous meta-analysis by Song et al provided mean ± SD or fold change of microRNAs expression levels in PCa patients vs controls,[@b21-cmar-11-2039] but did not provide diagnostic information, such as pooled SEN and SPE.

Limitations
===========

There were several limitations in our meta-analysis. First, the situation of unclear risk in the domains of patient selection and index could lower methodological qualities. Second, significant heterogeneities existed among included studies of miR-30c. Despite sensitive analysis being performed, potential sources of heterogeneities were still hard to been found. Third, comparison with blood-based specimen, tissue-based specimen is difficult to obtain in real life. Fourth, the number of included studies were few. It is necessary to adopt standardization of control group, specimen, and index test and to conducted more related studies.

Conclusion
==========

Our meta-analysis showed that, for PCa, miR-21 is a good diagnostic biomarker and miR-30c is a moderate diagnostic biomarker.

Supplementary material
======================

###### 

PRISMA Checklist

  Section/topic                        \#       Checklist item                                                                                                                                                                                                                                                                                                Reported on page \#
  ------------------------------------ -------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  **TITLE**                                                                                                                                                                                                                                                                                                                                                   
  Title                                1        Identify the report as a systematic review, meta-analysis, or both.                                                                                                                                                                                                                                           1
  **ABSTRACT**                                                                                                                                                                                                                                                                                                                                                
  Structured summary                   2        Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.   2
  **INTRODUCTION**                                                                                                                                                                                                                                                                                                                                            
  Rationale                            3        Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                                3
  Objectives                           4        Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                                                                                                                    3
  **METHODS**                                                                                                                                                                                                                                                                                                                                                 
  Protocol and registration            5        Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.                                                                                                                                 Not applicable
  Eligibility criteria                 6        Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.                                                                                                        4
  Information sources                  7        Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                    4
  Search                               8        Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                                 4 ([Table S2](#SD2-cmar-11-2039){ref-type="supplementary-material"})
  Study selection                      9        State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                                                                                                     4
  Data collection process              10       Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                                    4
  Data items                           11       List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.                                                                                                                                                                         5
  Risk of bias in individual studies   12       Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                        5
  Summary measures                     13       State the principal summary measures (e.g., risk ratio, difference in means).                                                                                                                                                                                                                                 5
  Synthesis of results                 14       Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., *I*^2^) for each meta-analysis.                                                                                                                                                     5--6
  **Section/topic**                    **\#**   **Checklist item**                                                                                                                                                                                                                                                                                            **Reported on page \#**
  Risk of bias across studies          15       Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).                                                                                                                                                                  6
  Additional analyses                  16       Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.                                                                                                                                                              6
  **RESULTS**                                                                                                                                                                                                                                                                                                                                                 
  Study selection                      17       Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                               6
  Study characteristics                18       For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.                                                                                                                                                                  6--7
  Risk of bias within studies          19       Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).                                                                                                                                                                                                     7
  Results of individual studies        20       For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.                                                                                                      7--8
  Synthesis of results                 21       Present results of each meta-analysis done, including confidence intervals and measures of consistency.                                                                                                                                                                                                       7--8
  Risk of bias across studies          22       Present results of any assessment of risk of bias across studies (see Item 15).                                                                                                                                                                                                                               7
  Additional analysis                  23       Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression \[see Item 16\]).                                                                                                                                                                                       8
  **DISCUSSION**                                                                                                                                                                                                                                                                                                                                              
  Summary of evidence                  24       Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).                                                                                                                          8--9
  Limitations                          25       Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).                                                                                                                                                 9
  Conclusions                          26       Provide a general interpretation of the results in the context of other evidence, and implications for future research.                                                                                                                                                                                       10
  **FUNDING**                                                                                                                                                                                                                                                                                                                                                 
  Funding                              27       Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.                                                                                                                                                                    13

###### 

Search strategy

        Search strategy
  ----- ---------------------------------------------------------------------------
        
  \#1   "microRNA" OR "miRNA" OR "miR" AND "prostate cancer" AND "diagnosis"
  \#2   "microRNA" OR "miRNA" OR "miR" AND "prostate cancer" AND "sensitivity"
  \#3   "microRNA" OR "miRNA" OR "miR" AND "prostate cancer" AND "specificity"
  \#4   "microRNA" OR "miRNA" OR "miR" AND "prostate carcinoma" AND "diagnosis"
  \#5   "microRNA" OR "miRNA" OR "miR" AND "prostate carcinoma" AND "sensitivity"
  \#6   "microRNA" OR "miRNA" OR "miR" AND "prostate carcinoma" AND "specificity"

###### 

Sensitivity analysis for pooled sensitivities and corresponding heterogeneities

  A                                                                                                                       
  ---------------------------------------------------------------------------- ------------------- ---------------------- -----------------------------------------------------
                                                                                                                          
  Porzycki et al[@b22-cmar-11-2039]                                            0.91(0.87--0.94)    0                      0.43
  Yang et al[@b23-cmar-11-2039],[c](#tfn6-cmar-11-2039){ref-type="table-fn"}   0.90 (0.85--0.94)   0                      0.58
  Yang et al[@b23-cmar-11-2039],[d](#tfn7-cmar-11-2039){ref-type="table-fn"}   0.90 (0.85--0.93)   0                      0.75
  Gao et al[@b24-cmar-11-2039]                                                 0.92 (0.88--0.95)   0                      0.58
  Huang et al[@b25-cmar-11-2039]                                               0.92 (0.87--0.95)   0                      0.61
  Kotb et al[@b26-cmar-11-2039]                                                0.91(0.88--0.94)    0                      0.434
                                                                                                                          
  **B**                                                                                                                   
                                                                                                                          
  **Study**[a](#tfn4-cmar-11-2039){ref-type="table-fn"}                        **SEN (95% CI)**    ***I*^2^ index (%)**   ***P***[b](#tfn5-cmar-11-2039){ref-type="table-fn"}
                                                                                                                          
  Zhu et al[@b27-cmar-11-2039]                                                 0.73(0.66--0.79)    78.3                   0.01
  Huang et al[@b28-cmar-11-2039]                                               0.72 (0.66--0.76)   71.3                   0.03
  Chen et al[@b29-cmar-11-2039],[c](#tfn6-cmar-11-2039){ref-type="table-fn"}   0.71 (0.65--0.76)   68.5                   0.04
  Chen et al[@b29-cmar-11-2039],[d](#tfn7-cmar-11-2039){ref-type="table-fn"}   0.76 (0.70--0.80)   33.4                   0.22

Notes: (A) miR-21, (B) miR-30c.

Given named study is omitted.

P-value of the Cochrane-Q test.

Control group consisted of patients with benign prostate disease.

Control group consisted of healthy people.
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![Flow diagram of study selection.](cmar-11-2039Fig1){#f1-cmar-11-2039}

![Quality assessment of miR-21 according to QUADAS-2 guidelines.\
**Note:** (**A**) Risk of bias, (**B**) applicability concerns.](cmar-11-2039Fig2){#f2-cmar-11-2039}

![Quality assessment of miR-30c according to QUADAS-2 guidelines.\
**Note:** (**A**) Risk of bias, (**B**) applicability concerns.](cmar-11-2039Fig3){#f3-cmar-11-2039}

![Forest plots of sensitivity and specificity for miR-21.](cmar-11-2039Fig4){#f4-cmar-11-2039}

![Forest plots of positive likelihood ratio and negative likelihood ratio for miR-21.\
**Abbreviation:** DLR, diagnostic likelihood ratio.](cmar-11-2039Fig5){#f5-cmar-11-2039}

![Forest plots of diagnostic score and diagnostic odds ratio for miR-21.](cmar-11-2039Fig6){#f6-cmar-11-2039}

![Summary receiver operating characteristic curves.\
**Note:** (**A**) miR-21, (**B**) miR-30c.\
**Abbreviations:** AUC, area under curve; SROC, summary receiver- operating characteristic; SENS, sensitivity; SPEC, specificity.](cmar-11-2039Fig7){#f7-cmar-11-2039}

![Forest plots of sensitivity and specificity for miR-30c.](cmar-11-2039Fig8){#f8-cmar-11-2039}

![Forest plots of positive likelihood ratio and negative likelihood ratio for miR-30c.\
**Abbreviation:** DLR, diagnostic likelihood ratio.](cmar-11-2039Fig9){#f9-cmar-11-2039}

![Forest plots of diagnostic score and diagnostic odds ratio for miR-30c.](cmar-11-2039Fig10){#f10-cmar-11-2039}

![Deeks' funnel plots.\
**Note:** (**A**) miR-21, (**B**) miR-30c.](cmar-11-2039Fig11){#f11-cmar-11-2039}

###### 

Characteristics of included studies

  Author                             Year   Country   Specimen                                             Control group   MiR as control   Case size   Control size   MiR as biomarker   Relative expression[a](#tfn1-cmar-11-2039){ref-type="table-fn"}   SEN    SPE    TP    FP   FN   TN
  ---------------------------------- ------ --------- ---------------------------------------------------- --------------- ---------------- ----------- -------------- ------------------ ----------------------------------------------------------------- ------ ------ ----- ---- ---- -----
                                                                                                                                                                                                                                                                                          
  Zhu et al[@b7-cmar-11-2039]        2018   China     Tissue[b](#tfn2-cmar-11-2039){ref-type="table-fn"}                   U6               187         187            miR-30c            Low                                                               0.72   0.80   135   37   52   150
  Porzycki et al[@b8-cmar-11-2039]   2018   Poland    Serum                                                HP              U6               20          10             miR-21             High                                                              0.90   0.75   18    2    2    8
  Yang et al[@b9-cmar-11-2039]       2016   China     Mononuclear cell                                     PBPD            miR-16           92          85             miR-21             High                                                              0.94   0.93   86    6    6    79
  Yang et al[@b9-cmar-11-2039]       2016   China     Mononuclear cell                                     HP              miR-16           92          97             miR-21             High                                                              0.95   0.93   87    7    5    90
  Gao et al[@b10-cmar-11-2039]       2016   China     Plasma                                               PBPD            U6               57          28             miR-21             High                                                              0.88   0.75   50    7    7    21
  Huang et al[@b11-cmar-11-2039]     2016   China     Tissue[b](#tfn2-cmar-11-2039){ref-type="table-fn"}                                    44          44             miR-30c            Low                                                               0.82   0.80   36    9    8    35
  Huang et al[@b12-cmar-11-2039]     2015   China     Mononuclear cell                                     HP              U6               75          75             miR-21             High                                                              0.88   0.86   66    11   9    64
  Kotb et al[@b13-cmar-11-2039]      2014   Egypt     Serum                                                PBPD            SNORD47          10          10             miR-21             High                                                              0.90   0.90   9     1    1    9
  Chen et al[@b14-cmar-11-2039]      2012   China     Plasma                                               HP              U6               80          54             miR-30c            Low                                                               0.79   0.69   64    17   16   37
  Chen et al[@b14-cmar-11-2039]      2012   China     Plasma                                               PBPD            U6               80          44             miR-30c            Low                                                               0.61   0.83   49    8    31   36

**Notes:**

Relative expression of miR-21 or miR-30c as biomarker in case group compared with control group.

Include PCa cancer tissue and PCa adjacent normal tissue, cancer tissue was regarded as case group and adjacent normal tissue as control group.

**Abbreviations:** PBPD, patients with benign prostate disease; HP, healthy people; SEN, sensitivity; SPE, specificity; TP, true positive; FP, false positive; FN, false negative; TN, true negative.
